May. 13 at 11:12 AM
Citizens⬇️
$PHVS's PT to
$74 (was
$75), reiterated at a Market Outperform, and said: The Phase 3 CHAPTER-3 readout coming in 3Q26 is the next key catalyst for shares.
$KALV $BCRX IONS TAK
Citizens added—In Phase 2, deucrictibant showed an ~85% attack reduction, which is in line with injectable prophylactics.
If confirmed in Phase 3, deucrictibant XR could emerge as a differentiated oral option in an increasingly competitive HAE landscape.
Meanwhile, the acute franchise is de-risked with robust RAPIDe-3 data supporting an NDA submission this quarter.
We assign deucrictibant a POS of 90% for HAE treatment and 70% in HAE prophylaxis, with peak sales of~
$950M and ~
$1.6B, respectively.
